Massarotti Claudia, Stigliani Sara, Maccarini Elena, Bovis Francesca, Ferraro Mattia Francesco, Gazzo Irene, Anserini Paola, Scaruffi Paola
Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal-Child Health (DiNOGMI), University of Genova, Genova, Italy.
UOS Physiopathology of Human Reproduction, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
World J Mens Health. 2022 Oct;40(4):561-569. doi: 10.5534/wjmh.220055. Epub 2022 Aug 16.
To assess whether mRNA and viral vector coronavirus disease 2019 (COVID-19) vaccines detrimentally affected semen parameters.
In this prospective study, we enrolled 101 men vaccinated for COVID-19 (76% received mRNA vaccines, 20% viral vector vaccines, 2% a mixed formulation, and for 2 men no information about vaccine type was available) in 2021 and with a previous semen analysis. For each man we compared semen parameters before and after vaccination.
Post-vaccine samples were obtained at a median of 2.3±1.5 months after the second dose. After vaccination, the median sample volume significantly decreased (from 3.0 to 2.6 mL, p=0.036), whereas the median sperm concentration, the progressive motility, and total motile sperm count increased (from 25.0 to 43.0 million/mL, p<0.0001; from 50% to 56%, p=0.022; from 34.8 to 54.6 million, p<0.0001, respectively). Thirty-four patients were oligospermic before the vaccine, and also in these patients we observed a significant increase of sperm parameters after vaccine. Finally, we confirmed the aforementioned results in men who received a mRNA or a viral vector vaccine.
The semen parameters following COVID-19 vaccination did not reflect any causative detrimental effect from vaccination, and for the first time we demonstrated that this applies to both mRNA and viral-vector vaccines. The known individual variation in semen and the reduced abstinence time before the post-vaccine sample collection may explain the increases in sperm parameters.
评估2019冠状病毒病(COVID-19)的信使核糖核酸(mRNA)疫苗和病毒载体疫苗是否对精液参数产生不利影响。
在这项前瞻性研究中,我们纳入了2021年接种过COVID-19疫苗的101名男性(76%接种了mRNA疫苗,20%接种了病毒载体疫苗,2%接种了混合制剂,2名男性没有疫苗类型信息),他们之前都进行过精液分析。对于每名男性,我们比较了接种疫苗前后的精液参数。
在接种第二剂疫苗后的中位数时间为2.3±1.5个月时采集了疫苗接种后的样本。接种疫苗后,样本体积中位数显著下降(从3.0毫升降至2.6毫升,p = 0.036),而精子浓度中位数、进行性运动能力和总活动精子数增加(分别从2500万/毫升增至4300万/毫升,p < 0.0001;从50%增至56%,p = 0.022;从3480万增至5460万,p < 0.0001)。34名患者在接种疫苗前为少精子症患者,在这些患者中我们也观察到接种疫苗后精子参数显著增加。最后,我们在接种mRNA疫苗或病毒载体疫苗的男性中证实了上述结果。
COVID-19疫苗接种后的精液参数并未反映出接种疫苗有任何因果关系的不利影响,并且我们首次证明这适用于mRNA疫苗和病毒载体疫苗。精液中已知的个体差异以及疫苗接种后样本采集前禁欲时间的缩短可能解释了精子参数的增加。